8-K: Treace Medical Concepts Reports Strong Q4 and Full-Year 2023 Results, Provides Optimistic 2024 Guidance

Treace Medical Concepts reported a 25% increase in fourth-quarter revenue and a 32% increase in full-year revenue for 2023, exceeding previous guidance, and anticipates significant progress towards profitability in 2024.

Summary

• Treace Medical Concepts reported a 25% increase in revenue for the fourth quarter of 2023, reaching $62.2 million, compared to $49.8 million in the same period of 2022.
• Full-year 2023 revenue reached $187.1 million, a 32% increase compared to $141.8 million in 2022, and exceeded the high end of the previously provided guidance range of $182 million to $186 million.
• The blended average revenue per Lapiplasty procedure kit sold was a record high of $6,437 in the fourth quarter of 2023, a 9% increase year-over-year, and $6,306 for the full year, a 10% increase over 2022.
• The company added 164 new active surgeons in the fourth quarter and 468 for the full year, ending 2023 with 2,855 active surgeons, a 20% increase year-over-year, representing 29% of the estimated 10,000 U.S. surgeons performing bunion surgery.
• Treace ended the fourth quarter of 2023 with 227 direct quota-carrying sales representatives, a 35% increase over year-end 2022, contributing 82% of the revenue in the fourth quarter.
• Gross margin was 81.6% in the fourth quarter and 81.2% for the full year 2023.
• The company reported a net loss of $6.3 million, or $0.10 per share, for the fourth quarter of 2023, and a net loss of $49.5 million, or $0.81 per share, for the full year.
• Adjusted EBITDA was $2.6 million in the fourth quarter of 2023, compared to a loss of $0.5 million in the same period of 2022, and a loss of $24.4 million for the full year, compared to a loss of $25.0 million in 2022.
• The company expects full-year 2024 revenue to be between $220 million and $225 million, representing an 18% to 20% growth over 2023.
• Treace anticipates significant progress towards Adjusted EBITDA breakeven for full-year 2024, with an expected improvement of approximately 50% compared to 2023.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to strong revenue growth, increased adoption of the Lapiplasty system, and a clear path towards profitability. The company's performance exceeded expectations, and the future outlook is optimistic.

Positives

• Revenue growth was strong, with a 25% increase in Q4 and 32% for the full year, exceeding previous guidance.
• The company achieved a record high blended average selling price per Lapiplasty kit in Q4 2023.
• The number of active surgeons using the Lapiplasty system increased by 20% year-over-year.
• The direct sales channel grew by 35% year-over-year and contributed a significant portion of revenue.
• Adjusted EBITDA improved significantly in Q4 2023, turning positive from a loss in the same period of 2022.
• The company has a strong cash position of $126.2 million as of December 31, 2023.
• Treace is making significant progress towards Adjusted EBITDA breakeven in 2024.
• The company has a robust pipeline of new technologies and is expanding its patent portfolio.
• The company is the fastest growing company in foot and ankle, one of the fastest-growing segments in Orthopaedics.

Negatives

• The company reported a net loss of $6.3 million in Q4 2023 and $49.5 million for the full year.
• Gross margin decreased slightly in both Q4 and full-year 2023 compared to the previous year.
• Operating expenses increased significantly in 2023 due to strategic investments in the sales channel and product innovation.
• The company is not yet profitable, with a full-year adjusted EBITDA loss of $24.4 million.

Risks

• The company is still operating at a loss, and achieving profitability is dependent on continued revenue growth and cost management.
• Increased operating expenses could impact the company's ability to achieve profitability targets.
• The company's future performance is subject to risks and uncertainties, including those related to competition and market conditions.
• The company's forward-looking statements are based on current assumptions and expectations, which may not materialize.

Future Outlook

Treace expects full-year 2024 revenue to be between $220 million and $225 million, representing 18% to 20% growth over 2023, and anticipates significant progress towards Adjusted EBITDA breakeven for full-year 2024, with an expected improvement of approximately 50% compared to 2023. The company also expects to be cash flow positive in 2025.

Management Comments

• John T. Treace, CEO, stated that he is very pleased with the significant efforts of the Treace team to serve customers and patients and successfully execute plans throughout 2023.
• The CEO also stated that the results demonstrate the underlying strength and effectiveness of strategic investments into the direct sales channel, targeted R&D initiatives, and direct-to-consumer programs.
• The CEO expressed confidence that the company has the right strategies in place to continue to deliver industry-leading growth and profitably scale the business in 2024 and beyond.

Industry Context

Treace Medical Concepts operates in the foot and ankle segment of the orthopaedics market, which is experiencing rapid growth. The company's focus on bunion correction with its Lapiplasty system positions it well within this growing market. The company is the fastest growing company in foot and ankle, one of the fastest-growing segments in Orthopaedics.

Comparison to Industry Standards

• Treace's 32% revenue growth for 2023 is significantly higher than the average growth rate of many established medical device companies, indicating strong market traction.
• The company's blended average selling price per Lapiplasty kit of $6,306 is a premium price point, reflecting the innovative nature of the technology.
• The addition of 468 new active surgeons in 2023 demonstrates the company's ability to expand its user base, which is a key driver of future growth.
• While the company is not yet profitable, the significant improvement in Adjusted EBITDA in Q4 2023 and the projected 50% improvement in 2024 indicate a clear path towards profitability.
• Compared to other publicly traded peers in the foot and ankle market, Treace is demonstrating a higher growth rate and is rapidly gaining market share.

Stakeholder Impact

• Shareholders are likely to react positively to the strong revenue growth and improved profitability outlook.
• Employees may be motivated by the company's success and growth prospects.
• Customers (surgeons) are likely to continue adopting the Lapiplasty system due to its clinical effectiveness and innovative features.
• Suppliers may benefit from the company's increased production and sales volume.
• Creditors may view the company as a lower risk due to its improved financial performance and outlook.

Next Steps

• The company will continue to focus on expanding its direct sales channel and increasing surgeon utilization.
• Treace will continue to invest in research and development to bring new technologies to market.
• The company will work towards achieving Adjusted EBITDA breakeven in 2024 and positive cash flow in 2025.
• The company will continue to present clinical data supporting the effectiveness of its Lapiplasty system.

Key Dates

Keywords

Lapiplasty, bunion, foot and ankle, medical devices, surgical procedures, orthopaedics, revenue growth, EBITDA, sales channel, medical technology